Incyte said total revenues for Q3 2025 were $1.37 billion, an increase of 20% compared to Q3 2024, and total net product revenues were $1.15 billion, an increase of 19%.

1. 01

   Incyte said total revenues for Q3 2025 were $1.37 billion, an increase of 20% compared to Q3 2024, and total net product revenues were $1.15 billion, an increase of 19%.

2. 02

   The company said Jakafi net product revenues for Q3 were $791 million, an increase of 7%, and Opzelura net product revenues were $188 million, an increase of 35%. Niktimvo net revenues were $46 million.

3. 03

   Incyte said it is raising its full-year 2025 net product revenue guidance to $4.23–$4.32 billion. The company raised Jakafi guidance to $3.050–$3.075 billion from prior guidance of $3,000–$3,050 million, and maintained Opzelura guidance at $630–$670 million.

4. 04

   The company reported GAAP net income for Q3 2025 of $424,169 thousand (compared to $106,456 thousand for Q3 2024) and cash, cash equivalents and marketable securities as of September 30, 2025 of $2.9 billion, compared to $2.2 billion as of December 31, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.